Today: 11 March 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics shares fell 8.7% to $25.76 Monday after the company set a 2026 net product sales target of $455–$470 million for its ZORYVE franchise. The company reported $99.2 million in net product revenue last quarter and ended September with $191.4 million in cash. Arcutis plans to expand its sales team by 20% and expects key clinical trial data in early 2026. The stock hit a session low of $25.51.
12 January 2026
··
Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences shares fell 8.5% to $26.08 in afternoon trading after the company reported preliminary 2025 revenue near $800 million, up 94%, but warned of significant prior-period adjustments. The company also announced a partnership with Everlywell to develop a blood-based early cancer detection test, with more details expected at the JPMorgan Healthcare Conference later Monday.
12 January 2026
··
HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

HealthEquity shares fell about 10% Monday after the company issued a cautious initial fiscal 2027 outlook, projecting revenue between $1.38 billion and $1.41 billion and an HSA cash yield near 3.75%. The stock last traded at $84.62, down $9.53. Executives will present at the J.P. Morgan Healthcare Conference on Tuesday. The company reaffirmed its 2026 guidance.
12 January 2026
··
Synchrony Financial stock slides on Trump’s 10% credit-card rate cap pitch — what investors watch next

Synchrony Financial stock slides on Trump’s 10% credit-card rate cap pitch — what investors watch next

Synchrony shares fell 8.2% to $79.76 after Donald Trump called for a one-year 10% cap on credit card interest rates, sparking fears of tighter regulation and profit declines. Analysts said such a cap would require congressional approval. Bread Financial, Capital One, and Barclays also saw declines. Separately, Synchrony expanded CareCredit integration with Fiserv’s Clover platform, now reaching over 40,000 providers.
12 January 2026
·
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics shares fell 11% to $17.46 Monday after announcing a U.S. FDA biologics license application for its lung cancer drug ivonescimab. The company also disclosed a clinical trial collaboration with GSK to test a combination regimen in solid tumors. Investors are watching for the FDA’s next procedural step and updates from the J.P. Morgan Healthcare Conference.
12 January 2026
·
Figure Technology Solutions stock drops nearly 10% after FIGR posts preliminary Q4 loan data

Figure Technology Solutions stock drops nearly 10% after FIGR posts preliminary Q4 loan data

Figure Technology Solutions shares fell 9.6% to $52.50 Monday after releasing preliminary Q4 metrics. The company reported $2.705 billion in Q4 consumer loan marketplace volume, up 131% from a year earlier, and $328 million in $YLDS stablecoin circulation. Investors are watching for Tuesday’s U.S. CPI report and the Fed’s January meeting for rate signals.
12 January 2026
··
Bread Financial (BFH) stock slides on Trump’s 10% credit-card rate cap push; what’s next

Bread Financial (BFH) stock slides on Trump’s 10% credit-card rate cap push; what’s next

Bread Financial shares fell 10.8% to $71.65 Monday after Donald Trump proposed a one-year 10% cap on credit card interest rates, with no details on enforcement. The selloff spread to other lenders, including Synchrony and Capital One. Analysts questioned the proposal’s viability, citing legal hurdles. Bread Financial reports earnings Jan. 29, with investors watching for commentary on policy risks.
12 January 2026
·····
GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

GeneDx shares fell about 14% to $115.75 Monday after releasing preliminary 2025 results and 2026 revenue guidance above analyst estimates. The company projected 2026 revenue of $540–$555 million and positive adjusted net income. Investors are awaiting CEO remarks at the Jan. 14 J.P. Morgan Healthcare Conference and the Feb. 23 earnings report for further details. The latest figures remain unaudited and subject to revision.
12 January 2026
·
Lemonade stock hits fresh 52-week high as LMND rallies; traders watch short interest and earnings

Lemonade stock hits fresh 52-week high as LMND rallies; traders watch short interest and earnings

Lemonade shares jumped 7.7% to $85.81 Monday, hitting a new 52-week high amid heavy short interest and volatile trading. About 20% of the float was shorted as of mid-December, raising the risk of sharp moves. Chief insurance officer John Peters sold 10,000 shares Jan. 6 at $80 under a pre-set plan. The next earnings report is expected Feb. 24.
12 January 2026
··
Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta Therapeutics shares fell 13% to $20.73 Monday after a preliminary update showed weaker-than-expected fourth-quarter sales for its Duchenne gene therapy, Elevidys. The company reported $110.4 million in Elevidys revenue for the quarter, below Wall Street’s $122 million estimate. Sarepta cited a severe flu season and delayed six patient infusions to 2026. Final results are due in late February.
12 January 2026
·
Abercrombie & Fitch stock slides 17% after outlook trim puts tariffs back on the tape

Abercrombie & Fitch stock slides 17% after outlook trim puts tariffs back on the tape

Abercrombie & Fitch shares fell 17.3% to $103.26 after the company cut its full-year sales growth forecast and lowered its holiday-quarter outlook. The retailer now expects fiscal 2025 net sales growth of at least 6%, down from a prior 6%–7% range, and factored in $90 million in tariff expenses. Investors are watching the ICR Conference this week for further updates on demand and pricing.
12 January 2026
·
Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio shares fell 17.7% to $6.62 Monday after announcing a licensing deal with Eisai and releasing initial sales data for its lung-cancer drug. Eisai will pay €50 million upfront for rights outside the U.S., China, and Japan, with further milestone payments possible. Fourth-quarter Ibtrozi sales met estimates, but investors appeared cautious on future prescription growth.
12 January 2026
····
First Majestic Silver stock jumps 7% as silver rips to a fresh record — what investors watch next

First Majestic Silver stock jumps 7% as silver rips to a fresh record — what investors watch next

First Majestic Silver shares jumped 7% to $20.24 Monday as silver surged 6.8% to $85.39 an ounce, drawing heavy trading volume. Peer miners also rallied, with Hecla Mining up nearly 9%. Investors await Tuesday’s U.S. inflation data, which could shift rate and metals forecasts. JPMorgan and other banks have delayed expectations for Fed rate cuts into 2026 or later.
12 January 2026
·
Sibanye Stillwater stock jumps as gold cracks $4,600, putting Jan. 29 strategy update in play

Sibanye Stillwater stock jumps as gold cracks $4,600, putting Jan. 29 strategy update in play

Sibanye Stillwater’s U.S. shares surged 7.3% to $16.79 Monday afternoon as gold broke above $4,600 an ounce, driven by renewed U.S. policy uncertainty. The miner announced a strategy update for Jan. 29, giving investors a new short-term focus. Other gold stocks, including Harmony Gold and Gold Fields, also posted sharp gains. Traders are watching the Federal Reserve’s Jan. 27-28 meeting for signals on rates.
12 January 2026
··
Nebius (NBIS) stock jumps on report of 800MW Kansas City-area data center plan

Nebius (NBIS) stock jumps on report of 800MW Kansas City-area data center plan

Nebius shares jumped 10.2% to $107.87 Monday after reports of an 800-megawatt AI data center campus planned near Kansas City. The $6.6 billion project, proposed for Independence, Missouri, would span up to 10 buildings and 400 acres, with construction expected to start in early 2026. Investors are watching local approvals and the pace of power infrastructure development.
12 January 2026
··
Pure Storage stock jumps nearly 8% as investor focus turns to insider filing, CPI and a Needham webcast

Pure Storage stock jumps nearly 8% as investor focus turns to insider filing, CPI and a Needham webcast

Pure Storage shares rose 7.9% to $72.29 on Monday, outpacing the broader market. A Friday filing showed founder John Colgrove transferred 200,000 shares as gifts between family trusts. Investors are watching Tuesday’s U.S. CPI report and Pure’s presentation at the Needham Growth Conference on Thursday. Peer stocks, including NetApp and Western Digital, also advanced.
12 January 2026
···
Gold Fields stock jumps as gold breaks $4,600; CPI and earnings in focus

Gold Fields stock jumps as gold breaks $4,600; CPI and earnings in focus

Gold Fields shares surged 6.7% to $48.73 in New York Monday after gold prices hit a record high, prompting gains across gold miners. The rally followed safe-haven buying and a weaker dollar ahead of Tuesday’s U.S. inflation report. Gold Fields earlier touched $49.58, with Newmont, AngloGold Ashanti, and Wheaton Precious Metals also advancing. Investors await CPI data for clues on rates and sector momentum.
12 January 2026
·······
1 … 246 247 248 249 250 … 584
Go toTop